Acta Neuropharmacologica ›› 2017, Vol. 7 ›› Issue (1): 45-52.DOI: 10.3969/j.issn.2095-1396.2017.01.006

Previous Articles     Next Articles

Progress on Adipokines Participating in Alzheimer’s Disease

LUO Piao,CHU Shi-feng,CHEN Nai-hong   

  1. 1. College of Pharmacy,Hunan University of Chinese Medcine,410208,China
    2. Neuroscience Center,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100050,China
  • Online:2017-02-26 Published:2017-12-01
  • Contact: 陈乃宏,男,博士,研究员,博士生导师;研究方向:神经系统疾患创新药物开发及作用机制;E-mail:chennh@ imm.ac.cn
  • About author:罗飘,男,硕士研究生;研究方向:神经药理学和中药药理学;E-mail:luopiao168@163.com
  • Supported by:
    国家自然科学基金项目(No.81274122、81373997、81273629、21272278、U1402221、81260650),北京市自然科学基金项目(No.7131013 7142115),湖南省重点研发计划项目(No. 2015SK2029-1),湖南省教育厅高校科研经费开放基金项目(No.15K091),新药作用机制研究与药效评价北京市重点实验室资助项目(No.BZ0150)

Abstract: Alzheimer’s disease(AD),also called senile dementia,is one of the most common central neurodegenerative disease in the elderly. And its main pathological changes include the senile plaques formed by β-amyloid protein deposition out of the neuron, neurofibrillary tangles caused by the hyperphosphorylated tau protein in the neuron,and neurons in large number of loss and damage. Recently,the study has showed that Adipokine has closed relationship between β-amyloid protein deposition,hyperphosphorylated tau protein and neuronal apoptosis. This paper is mainly about the effect and mechanism of Adipokine,such as adiponectin,leptin,interleukin-6 and so on,on AD,which aims to provide a new ideas for the clinical treatment of AD.

Key words: Alzheimer&, rsquo, s disease, adipokine, adiponectin, leptin, interleukin-6

CLC Number: